CARTITUDE-1 Study Demonstrates Promising Response Rates in Relapsed/Refractory Myeloma
Jesus G. Berdeja, MD, discusses the findings from the phase 2 results of ciltacabtagene autoleucel as treatment of patients with relapsed/refractory multiple myeloma in the CARTITUDE-1 study.
Jesus G. Berdeja, MD, director of Myeloma Research at Sarah Cannon Research Institute, discusses the findings from the phase 2 results of ciltacabtagene autoleucel (cilta-cel; JNJ-68284528) as treatment of patients with relapsed/refractory multiple myeloma in the CARTITUDE-1 study (NCT03548207).
Researchers were gratified by the results seen in this study, says Berdeja, especially in regard to the response rates. The objective response rate was 97% with 57% of patients achieving a stringent complete response and 92% a partial response or better.
According to Berdeja, the median progression-free survival had not been reached yet, but at 12-months, 76.6% of patients remained in remission in the study.
Fedratinib Shows Promise in Chronic Neutrophilic Leukemia and MDS/MPN
January 20th 2025In an interview, Andrew Kuykendall, MD, discussed fedratinib’s potential as an effective option for patients with myelodysplastic syndrome/myeloproliferative neoplasms and chronic neutrophilic leukemia.
Read More
